Clinical trial NCT02641002: A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Official title: A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Keywords: CC-90002
Monoclonal
Antibody
CD47
Hematologic Cancers
Acute Myeloid Leukemia
AML
Myelodysplastic syndrome
MDS
Blood disorder
Lead sponsor: Celgene
Sponsor class: INDUSTRY
First posted: 2015-12-29
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and high-risk MDS. The study will explore escalating doses of CC-90002 using a 3 + 3 dose escalation design in Part A, followed by dose expansion in Part B.

The primary objective is to determine the safety and tolerability of CC-90002 and also to define the non-tolerated dose (NTD), the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-90002.

Detailed description: In both Part A and Part B, treatments will be administered in two phases starting with an induction phase followed by a maintenance phase. During the induction phase, treatments will be administered in 42-day cycles in Cycles 1 through 4. Following completion of Cycle 4 in the induction phase, subjects with non-progressive disease will enter the maintenance phase. During the maintenance phase, treatments will be administered in 28 day cycles. Subjects may continue CC-90002 for up to a maximum of 2 years (eg, induction phase Cycles 1 through 4 and maintenance phase Cycles 5 through 24) or until clinically significant disease progression, the occurrence of intolerable toxicity, or physician/subject decision to discontinue CC-90002, whichever comes first.

Eligibility criteria: Inclusion Criteria:

1. Men and women ≥ 18 years of age, at the time of signing the informed consent form (ICF).
2. Relapsed and/or primary refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) with subtype refractory anemia with excess blasts (RAEB)-2 defined as high or very high-risk that is recurrent or refractory, or the patient is intolerant to established therapy.
3. Subject consents to hospitalization for first (Cycle 1 Day 1) dose of CC-90002 and for 72 hours after.
4. Subject consents to serial bone marrow aspiration and biopsies as specified.
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.
6. Eligible study subjects must exhibit acceptable liver, renal, and coagulation function as assessed by laboratory tests.
7. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and for up to 8 weeks following the last dose of CC 90002.

Exclusion Criteria:

1. Active central nervous system (CNS) leukemia or known CNS leukemia.
2. Immediately life-threatening, severe complications of leukemia.
3. Impaired cardiac function or clinically significant cardiac diseases.
4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
5. Prior autologous hematopoietic stem cell transplant ≤ 3 months.
6. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months.
7. Systemic immunosuppressive therapy post HSCT or with clinically significant graft-versus-host disease (GVHD).
8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks whichever is shorter.
9. Major surgery ≤ 2 weeks and recovered from any clinically significant effects of recent surgery.
10. Pregnant or nursing females.
11. Known HIV infection.
12. Known chronic hepatitis B or C (HBV/HCV) infection.
13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
15. History of concurrent second cancers requiring active, ongoing systemic treatment.
16. Subjects for whom potentially curative anticancer therapy is available.

Primary outcomes:
measure: Dose-limiting Toxicity (DLT)
timeFrame: Up to 26 months
measure: Non-tolerated Dose (NTD)
timeFrame: Up to 26 months
measure: Maximum tolerated dose (MTD)
timeFrame: Up to 26 months
Secondary outcomes:
measure: Preliminary Efficacy of CC-90002
timeFrame: Up to 35 months
measure: Pharmacokinetics-Cmax
timeFrame: Up to 35 months
measure: Pharmacokinetics-AUC
timeFrame: Up to 35 months
measure: Pharmacokinetics-Tmax
timeFrame: Up to 35 months
measure: Pharmacokinetics-T 1/2
timeFrame: Up to 35 months
measure: Pharmacokinetics- CL
timeFrame: Up to 35 months
measure: Pharmacokinetics- Vss
timeFrame: Up to 35 months
measure: Anti-Drug Antibodies (ADAs)
timeFrame: Up to 35 months
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic Phoenix
state: Arizona
city: Los Angeles
country: United States
facility: UCLA Division of Hematology Oncology
state: California
city: New Haven
country: United States
facility: Yale Cancer Center
state: Connecticut
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Celgene Corporation
name: Michael Burgess, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K. Modulation of CD47-SIRPalpha innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunol Immunother. 2022 Feb;71(2):473-489. doi: 10.1007/s00262-021-03010-6. Epub 2021 Jul 10.